Summary by Moomoo AI
Senti Biosciences, a biotechnology company specializing in gene circuit technologies for cell and gene therapies, reported a net loss of $28.9 million for the third quarter of 2024, compared to a net loss of $14.9 million for the same period in 2023. The company's net losses for the nine months ended September 30, 2024, were $52.2 million, slightly down from $52.3 million for the same period in 2023. As of September 30, 2024, Senti had cash and cash equivalents of $10.5 million, down from $35.9 million at the end of 2023, and an accumulated deficit of $296.5 million. Operating expenses for the quarter were $15.2 million, a significant decrease from $44.2 million in the previous year, primarily due to a reduction in impairment of long-lived assets. Research and development expenses for the quarter were $8.7 million...Show More
